Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 1, 2013, Pages 4-15

  Grundman, Michael ^a,b   Pontecorvo, Michael J ^d   Salloway, Stephen P ^e   Doraiswamy, P Murali ^f   Fleisher, Adam S ^b,g   Sadowsky, Carl H ^h   Nair, Anil K ⁱ   Siderowf, Andrew ^d   Lu, Ming ^d   Arora, Anupa K ^d   Agbulos, Abigail ^d   Flitter, Matthew L ^d   Krautkramer, Michael J ^d   Sarsour, Khaled ^c   Skovronsky, Daniel M ^d   Mintun, Mark A ^d  

^a Global R and D Partners LLC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d AVID RADIOPHARMACEUTICALS   (United States)

^e BUTLER HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g BANNER ALZHEIMER S INSTITUTE   (United States)

^h NOVA SOUTHEASTERN UNIVERSITY   (United States)

ⁱ Quincy Medical Center   (United States)

Author keywords

Alzheimer diagnosis; Alzheimer management; PET amyloid imaging

Indexed keywords

AMYLOID; CHOLINESTERASE INHIBITOR; FLORBETAPIR F 18; MEMANTINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL EVALUATION; COGNITIVE DECLINE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MORBIDITY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; ANILINE COMPOUNDS; ETHYLENE GLYCOLS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PHYSICIAN'S PRACTICE PATTERNS; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84874241691     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318279d02a     Document Type: Article

References (38)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
2. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc. 1999;47:564-569.
3. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338: 506-511.
4. Ranginwala NA, Hynan LS, Weiner MF, et al. Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008;16:384-388.
5. Beach TG, Monsell SE, Phillips LE, et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-273.
6. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
7. Solomon PR, Brush M, Calvo V, et al. Identifying dementia in the primary care practice. Int Psychogeriatr. 2000;12:483-493.
8. Lopponen M, Raiha I, Isoaho R, et al. Diagnosing cognitive impairment and dementia in primary health care - a more active approach is needed. Age Ageing. 2003;32:606-612.
9. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
10. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
11. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-1127.
12. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306-319.
13. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210-1217.
14. Koole M, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med. 2009;50:818-822.
15. Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;51:913-920.
16. Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378-384.
17. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-b plaques: a prospective cohort study. Lancet Neurol. 2012;11:669-678.
18. Leinonen V, Alafuzoff I, Aalto S, et al. Assessment of betaamyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch Neurol. 2008;65:1304-1309.
19. Sojkova J, Driscoll I, Iacono D, et al. In vivo fibrillar betaamyloid detected using [11C] PiB positron emission tomography and neuropathologic assessment in older adults. Arch Neurol. 2011;68:232-240.
20. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging. 2012;33:2091-2105.
21. Burack MA, Hartlein J, Flores HP, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74:77-84.
22. Consensus recommendations for the post-mortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18:S1-S2.
23. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid b assessed by florbetapir F18 PET and 18 month cognitive decline. Neurology. 2012;79:1636-1644.
24. Landau SM, Mintun MA, Joshi AD, et al. for the Alzheimer's Disease Neuroimaging Initiative. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578-586.
25. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir- PET for imaging beta-amyloid pathology. JAMA. 2011;305: 275-283.
26. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57: 1168-1174.
27. Price JL, Morris JC. Tangles and plaques in non-demented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358-368.
28. Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-1411.
29. Armstrong RA, Cairns NJ, Lantos PL. Beta-amyloid (A beta) deposition in the medial temporal lobe of patients with dementia with Lewy bodies. Neurosci Lett. 1997;227:193-196.
30. Hainfellner JA, Wanschitz J, Jellinger K, et al. Coexistence of Alzheimer type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol. 1998;96:116-122.
31. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
32. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16:203-212.
33. Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloidbeta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122-131.
34. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Arlington, VA: American Psychiatric Association (APA); 2007.
35. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS- ADRDA criteria. Lancet Neurol. 2007;6:734-746.
36. Schipke CG, Peters O, Heuser I, et al. Impact of beta-amyloidspecific florbetaben PET Imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:416-422.
37. Kupsch AR, Bajaj N, Weiland F, et al. Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidenceof diagnosis, quality of life, health resource use and safety in patients with clinically uncertain Parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study. J Neurol Neurosurg Psychiatry. 2012;83:620-628.
38. Staub KP, Lord SJ, Simes RJ, et al. Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation. BMC Med Res Methodol. 2012;12:12.